SCHEMBL1353088

SCHEMBL1353088

CCN(C(=O)c1ccc(C(C)=O)cc1)C1CCCCC1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.65
NPC1 O15118 1/20 0.65
RAB9A P51151 1/20 0.65
HSD11B1 P28845 3/20 0.64
ADORA2A P29274 4/20 0.51
AGER Q15109 3/20 0.50
BRD4 O60885 1/20 0.50
MTNR1A P48039 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
TSHR P16473 1/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
KDM4E B2RXH2 1/20 0.48
ALOX15 P16050 1/20 0.48
ALOX12 P18054 1/20 0.48
RECQL P46063 1/20 0.48
ADAM17 P78536 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10722280 0.94 HSD11B1 (0.70) LMNANPC1RAB9AHSD11B1ADORA2A
SCHEMBL96038 0.86 HSD11B1 (0.62) LMNANPC1RAB9AHSD11B1ADORA2A
SCHEMBL4486060 0.86 HSD11B1 (0.61) LMNANPC1RAB9AHSD11B1ADORA2A
SCHEMBL4139952 0.86 L3MBTL1 (0.62) LMNAHSD11B1ADORA2AAGERMTNR1A
SCHEMBL1356197 0.84 HSD11B1 (0.60) LMNANPC1RAB9AHSD11B1ADORA2A
SCHEMBL1354645 0.83 HSD11B1 (0.53) LMNANPC1RAB9AHSD11B1ADORA2A
SCHEMBL1354666 0.82 ADORA2A (0.61) LMNANPC1RAB9AHSD11B1ADORA2A
SCHEMBL10720234 0.81 HSD11B1 (0.56) LMNANPC1RAB9AHSD11B1AGER
SCHEMBL1355162 0.81 TSHR (0.53) LMNANPC1RAB9AHSD11B1ADORA2A
SCHEMBL1354697 0.81 HSD11B1 (0.54) LMNANPC1RAB9AHSD11B1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9029393-B2 Adenosine receptor ligands and uses thereof KALDI PHARMA, SAS (FR) 2015-05-12 US disclosed
CN-102365280-B adenosine receptor ligands and uses thereof DOMAIN THERAPEUTICS (FR) 2014-10-29 CN disclosed
EP-2391625-B1 New adenosine receptor ligands and uses thereof DOMAIN THERAPEUTICS (FR) 2013-05-01 EP disclosed
EP-2391625-A1 NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF Domain Therapeutics (FR) 2011-12-07 EP disclosed
US-20110288074-A1 NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF DOMAIN THERAPEUTICS (FR) 2011-11-24 US disclosed
WO-2010084425-A1 NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF DOMAIN THERAPEUTICS (FR) 2010-07-29 WO disclosed
EP-2210891-A1 New adenosine receptor ligands and uses thereof Domain Therapeutics (FR) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288074-A1 NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF ADORA2A, ADORA1, ADORA2B LMNA 3802/4885NPC1 1152/4885RAB9A 1899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.